Hepatitis C: State of the Art at the Millennium, Part 1

Front Cover
Andrea D. Branch, Leonard B. Seeff, Charles L. Branch, Jr.
Thieme, 2000 - Medical - 246 pages
0 Reviews

A hardbound compendium of Volume 20, Numbers 1 and 2 of the journal, Seminars
in Liver Disease, this new volume brings together an international group of
distinguished authors to present 16 current, incisive reviews and analyses of
both the basic science and clinical aspects of HCV.


The volume examines the broadest spectrum of HCV virology, pathology, and
disease while focusing on the following key issues:


  • HCV's impact on human populations
  • The manifestations of the virus & its
    distribution throughout the body
  • HCV molecular virology with an emphasis on its
    clinical implications
  • Identification of pharmaceutical targets and vaccine
    components and an analysis of genotypes and interferon sensitivity

In addition, the volume examines the clinical consequences of HCV infection,
including immune response to HCV, B-cell abnormalities, diagnostic tests,
kinetic studies, interferon-ribavirin combination therapy, liver
transplantation, and vaccine development.



 

What people are saying - Write a review

We haven't found any reviews in the usual places.

Contents

Geographic Differences and Temporal Trends
1
Transmission Natural History and Treatment of Hepatitis C Virus Infection
37
Detection and Significance
47
Does It Also Trigger
57
Biochemical and Immunologic Properties of the Nonstructural Proteins of
69
Distribution of Markers of HCV Infection Throughout the Body
85
Clinical Significance of Hepatitis C Virus Genotypes and Quasispecies
103
Interaction between the Hepatitis C Virus and the Immune System
127
Autoimmunity Mixed
143
Diagnostic Testing for Hepatitis C
159
Mathematical Modeling of Viral Response to Therapy
173
Hepatitis C after Liver Transplantation
201
DIAGNOSTIC PROBLEMS IN HEPATOLOGY
227
Copyright

Other editions - View all

Common terms and phrases

Popular passages

Page 182 - 7. Poynard T, Marcellin P. Lee SS, et al. Randomized trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet l998;352:
Page 168 - P. Lee 55, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet l998;352:
Page 66 - 5. Martell M, Esteban JI, Quer J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992; 66:3225—3229
Page 34 - Non-A/non-B hepatitis: A review and interim report of an ongoing prospective study. In: Vyas GN, Cohen SN, Schmid R, eds. Viral Hepatitis: A Contemporary Assessment of Etiology, Epidemiology, Pathogenesis and Prevention. Philadelphia: Franklin Institute Press,
Page 222 - Weiner AJ, Geysen HM, Christopherson C, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections. Proc Natl Acad Sci USA 1992;89:3468—3472
Page 33 - Kiyosawa K, Sodeyama T, Tanaka E, et al. interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology
Page 124 - Weiner AJ, Geysen HM, Christopherson C, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infection. Proc NatI Acad Sci USA
Page 53 - Knodell KG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology
Page 197 - 9. Marcellin P. Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-a therapy. Ann Intern Med

About the author (2000)

National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland

Bibliographic information